UNSPSC 51202419: Dinutuximab

A GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

UNSPSC 51202419 Dinutuximab, a Commodity code, shows minimal alignment between its nominal scope and recent state and local solicitation activity. The code designates a specific monoclonal antibody immunotherapy, yet the four recent opportunities posted under it span naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, emergency medical and first aid supplies, and generic multi-source pharmaceuticals and over-the-counter products — none of which are dinutuximab or closely related oncology therapeutics. The mismatch suggests either inconsistent coding by issuing bodies or a data tagging error rather than genuine procurement activity under the code's stated scope.

The recent opportunities originate from diverse issuing bodies: Seminole County, Florida (health department); the Texas Health and Human Services Commission (state agency); the City of Tampa (municipal fire department); and the Minnesota Multistate Cooperative Purchasing Alliance (cooperative purchasing vehicle). Activity concentrates in Florida, Texas, and Minnesota, with the Minnesota RFP also serving Oregon participants. The Seminole County IFB (due July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually; the City of Tampa IFB (due March 13, 2026) for emergency medical supplies for the fire rescue division carried an estimated value of $700,000 and included a 5% small local business enterprise discount; the Minnesota MMCAP RFP (due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers; and the Texas HHS RFI (due April 3, 2026) gathered preliminary market intelligence on direct-to-manufacturer prescription fulfillment models. No recent opportunities directly procure dinutuximab or related oncology therapeutics under this code.